SOUTH SAN FRANCISCO, Calif., June 4, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it received approval from the NASDAQ Listing Qualifications Department to transfer the listing of its common stock from the NASDAQ Global Market to the NASDAQ Capital Market. The transfer was effective as of June 3, 2008.
